profit from every €100 of sales.
€0€100
Amplifon
€12.12-1.38% today
-12.7% since Dec 16, 25
1-year low €8.031-year high €14.14
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €35.25 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Amplifon sold, what it kept, and what it did with the cash.
Sales went from €2.12 billion in 2022 to €2.40 billion in 2025, with €91.3 million of profit last year.
SalesProfit
Amplifon handed back 59% of the cash it generated last year.
Buybacks €108M€65M
Free cash flow 2025€296M
Bought back its own shares€108M
Paid as dividends€65M
Cash vs. debt€309M vs. €1.8B
Amplifon vs. similar companies
Amplifon grows the slowest of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Amplifon | 35.3× · Expensive | ||
 McKesson | 25.7× · Fair price | ||
 Cencora | 42.5× · Expensive | ||
 Cardinal Health | 40.6× · Expensive | ||
 Sigma Healthcare | 62.1× · Very expensive |
AI analysis
An AI analyst reads Amplifon's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,119 | 2,260 | 2,409 | 2,396 | |
| 1,175 | 1,270 | 1,364 | 1,281 | |
| 267 | 251 | 253 | 205 | |
| 514 | 522 | 557 | 507 | |
| 179 | 155 | 145 | 91 | |
| 0.79 | 0.69 | 0.65 | 0.42 | |
| 55.5% | 56.2% | 56.6% | 53.5% | |
| 12.6% | 11.1% | 10.5% | 8.5% | |
| 8.4% | 6.9% | 6.0% | 3.8% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3,575 | 3,693 | 3,993 | 3,893 |
| Cash | 180 | 193 | 289 | 309 |
| Total debt | 1,504 | 1,518 | 1,726 | 1,821 |
| Total liabilities | 2,535 | 2,592 | 2,843 | 2,894 |
| 1,039 | 1,101 | 1,150 | 998 | |
| 227 | 226 | 225 | 220 | |
| 8.2% | 7.4% | 6.7% | 5.2% | |
| 17.2% | 14.1% | 12.6% | 9.1% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 459 | 414 | 451 | 415 | |
| 116 | 142 | 146 | 118 | |
| 343 | 272 | 305 | 296 | |
| Dividends paid | 58 | 65 | 66 | 65 |
| 54 | 0 | 26 | 108 | |
| – | – | – | – |
Valuation
- 35.3×
- –
- –
- 3.2×
- 1.3×
- 10.9×
- 9.3×
- 9.2%
- 2.8%
- 2.0%
Profitability
- 53.5%
- 8.5%
- 3.8%
- –
- 5.2%
- 6.9%
- –
- –
- –
- –
Growth
- +4.2%
- −19.2%
- –
- –
- −1.0%
Financial health
- 3.0×
- 1.82
- –
- 3.2×
- 0.61
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 948
Top 50%of 871
Bottom 39%of 560
Bottom 25%of 868
Top 9%of 985
2.0%of the share price, paid each year
On $1,000 invested$20a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
71.5% of its profit
Room to growStretchedMore than it earns: 22.0%
News
KKR & Co. Non-GAAP EPS of $1.78 beats by $0.20, revenue of $4.56BSeeking Alpha · Nov 9, 2026C&F Financial Non-GAAP EPS of $2.55Seeking Alpha · Oct 26, 2026S&T Bancorp GAAP EPS of $1.09 beats by $0.10, revenue of $107.8M beats by $1.08MSeeking Alpha · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
26No pass
Philip Fisher
33No pass
Peter Lynch
15No pass
Joel Greenblatt
12No pass
Charlie Munger
22No pass
Terry Smith
23No pass
Questions about Amplifon
Is Amplifon a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Amplifon AI analysis
What does Amplifon do?
Amplifon S.p.A. distributes hearing solutions and the fitting of customized products that helps people to rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. It is in Medical Distribution, based in Milan, MI, Italy, with 11,792 employees.
Does Amplifon pay a dividend?
Yes. At today's price the dividend is 2.0% a year, about 71% of its yearly profit. In 2025 it paid out €65.3 million in dividends.
Is Amplifon stock halal?
No. Amplifon does not pass our halal screen: its debt is 57% of its market value, at or above the 33% limit. How we check
Who are Amplifon's competitors?
The largest listed companies in the same industry are McKesson, Cencora, Cardinal Health and Sigma Healthcare. The peers table on this page compares their profit, growth and price with Amplifon's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.